A novel and lethal De Novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Bankston, John R ^a   Yue, Minerva ^a   Chung, Wendy ^a   Spyres, Meghan ^a   Pass, Robert H ^a   Silver, Eric ^a   Sampson, Kevin J ^a   Kass, Robert S ^a  

^a Columbia University Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESMOLOL; FLECAINIDE; LIDOCAINE; MAGNESIUM; MEXILETINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNH2; PROPRANOLOL; RANOLAZINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL SCN5A; MUSCLE PROTEIN; SCN5A PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; ATRIOVENTRICULAR BLOCK; BIOPHYSICS; CASE REPORT; CELL STRAIN HEK293; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG MEGADOSE; DRUG RESPONSE; ELECTROCARDIOGRAPHY; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; LONG QT SYNDROME; MISSENSE MUTATION; MUTANT; NEWBORN; PATCH CLAMP; PHARMACOGENETICS; PHENOTYPE; QT INTERVAL; QT PROLONGATION; SEQUENCE ANALYSIS; TORSADE DES POINTES; WILD TYPE; DRUG EFFECT; GENETICS; LETHAL GENE; MALE; MUTATION;

GENES, LETHAL; HUMANS; INFANT, NEWBORN; LONG QT SYNDROME; MALE; MUSCLE PROTEINS; MUTATION; SODIUM CHANNELS;

EID: 43449097536     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001258     Document Type: Article

References (43)

1. Moss AJ, Kass RS (2005) Long QT syndrome: from channels to cardiac arrhythmias. J Clin Invest 115: 2018-2024.
2. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, et al. (2006) Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114: 2104-2112.
3. Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, et al. (2007) SCN4B-ecncoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 116: 134-142.
4. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, et al. (2005) Safety and efficacy of flecainide in subjects ith Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 10: 59-66.
5. Kass RS, Moss AJ (2006) Mutation-Specific pharmacology of the long QT syndrome. Handb Exp Pharmacol. pp 287-304.
6. Schwartz PJ, Crotti L (2007) Cardiac arrhythmias of genetic origin are important contributors to sudden infant death syndrome. Heart Rhythm 4: 740-742.
7. Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, et al. (2007) Prevalence of long-QT syndrome gene variants in sudden infant death syndrome, Circulation 115: 361-367.
8. Wang DW, Desai RR, Crotti L, Arnestad M, Insolia R, et al. (2007) Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation 115: 368-376.
9. Ten Harkel AD, Witsenburg M, de Jong PL, Jordaens L, Wijman M, et al. (2005) Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias. Europace 7: 77-84.
10. Wedekind H, Smits JP, Schulze-Bahr E, Arnold R, Veldkamp MW, et al. (2001) De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation 104: 1158-1164.
11. Schulze-Bahr E, Fenge H, Etzrodt D, Haverkamp W, Monning G, et al. (2004) Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart 90: 13-16.
12. Clancy CE, Rudy Y (1999) Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature 400: 566-569.
13. Lerche H, Peter W, Fleischhauer R, Pika-Hartdaub U, Malina T, et al. (1997) Role in fast inactivation of the IV/S4-S5 loop of the human muscle Na+ channel probed by cysteine mutagenesis. J Physiol 505 (Pt 2): 345-352.
14. Sthwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, et al. (1995) Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92: 3381-3386.
15. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, et al. (2000) Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 101: 1698-1106.
16. Fredj S, Sampson KJ, Liu H, Kass RS (2006) Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 148: 16-24.
17. Nagatomo T, January CT, Makielski JC (2000) Preferential block of late sodium current in the LQT3 Delta KPQ mutant by the class I(C) antiarrhythmic flecainide. Mol Pharmacol 57: 101-107.
18. Liu H, Atkins J, Kass RS (2003) Common molecular determinants of flecainide and lidocaine block of heart na(+) channels: evidence fiom experiments with neutral and-quaternary flecainide analogues. J Gen Physio1 121: 199-214.
19. Clanck CE, Tateyama M, Liu H, Wehrens XH, Kass RS (2003) Non-equilibrium gating in cardiac Na+ channels: an original mechanism of arrhythmia. Circulation 107: 2233-2237.
20. Wang DW, Yazawa K, Makita N, George AL, Bennett PB (1997) Pharmacological Targeting of Long QT Mutant Sodium Channels. Journal of Clinical Investigation 99: 1714-1720.
21. Clancy CE, Tateyama K, Kass RS (2002) Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. J Clin Invest 110: 1251-1262.
22. ten Tusscher KH, Noble D, Noble PJ, Panfilov, AV (2004) A model for human ventricular tissue. Am J Physiol Heart Circ Physiol 286: H1573-1589.
23. Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, et al. (2000) A molecular link between the sudden infant death syndrome and the long-QT syndrome, N Engl J Med 343: 262-267.
24. Miura M, Yamagishi H, Morikawa Y, Matsuoka R (2003) Congenital long QT syndrome and 2:1 atrioventricular block with a mutation of the SCN5A gene. Pediatr Cardiol 24: 70-72.
25. Plant LD, Bowers PN, Liu Q. Morgan T, Zhang T, et al. (2006) A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest 116: 430-435.
26. Kehl H, Haverkamp W, Rellensmann O, Yelbuz T, Krasemann T, et al. (2004) Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3. Circulation 109: e005-206.
27. Ackerman MJ, Sru BL, Sturner WQ, Tester DJ, Valdivia CR, et al. (2001) Postmortem molecular analvsis of SCN5A defects in sudden infant death syndrome. Jama 286: 2264-2269.
28. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, et al. (2005) Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. Jama 294: 2975-2980.
29. Kambouris NG, Nuss HB, Johns DC, Tomaselli,GF, Marban E, et al. (1998) Phenotypic characterizition of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Circulation 97: 640-644.
30. Bennett PB, Yazawa K, Makita, N, George AL Jr (1995) Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685.
31. Abriel H, Cabo C, Wehrens XH, Rivolta I, Motoike HK, et al. (2001) Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. Circ Res 88: 740-745.
32. Nerbonne JM (1998) Regulation of voltage-gated K+ channel expression in the developing mammalian myocardium. J Neurobiol 37: 37-59.
33. Obreztchikova MN, Sosunov EA, Plotnikov A, Anyukhovsky EP, Gainullin RZ, et al. (2003) Developmental changes in IKr and IKs contribute to age-related expression of dofetilide effects on repolarization and proarrhythmia. Cardiovasc Res 59: 339-350.
34. Nagashima M, Tohse N, Kimura K, Yamada Y, Fujii N, et al. (2001) Alternation of inwardly rectifying background K+ channel during development of rat fetal cardiomyocytes. J Mol Cell Cardiol 33: 533-543.
35. Wang DW, Kiyosue T, Sato T, Arita M (1996) Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes. J Mol Cell Cardiol 28: 893-903.
36. Paul AA, Witchel HJ, Hancox JG (2002) Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136: 717-729.
37. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, et al. (2003) Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 78: 1479-1487.
38. Koo SH, Ho WF, Lee EJ (2006) Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore: Br J Clin Pharmacol 61: 301-308.
39. Paavonen KJ, Chapman H, Laitinen PJ, Fodstad H, Piippo K, et al, (2003) Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG). Cardiovasc Res 59: 603-611.
40. Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, et al. (2003) A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 59: 27-36.
41. Anson BD, Ackerman MJ, Tester DJ, Will ML, Delisie BP, et al. (2004) Molecular and FunctionaJ characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol 286: H2434-2441.
42. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, et al (2005) KCNH2-K897T is a genetic modifier of latent congenital long-JQT syndrome. Circulation 112: 1251-1258.
43. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG (2007) Gaturg properties of SCN5A: mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 116: 1137-1144.